CBT CABOT CORP
Miscellaneous Chemical Products · NYSE · SEC CIK 16040 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.7%
TTM net income YoY-55.3%
TTM EPS YoY-53.3%
Revenue 3-yr CAGR-3.8%
Net income 3-yr CAGR-14.6%
Margins
Gross margin22.7%
Operating margin13.6%
Net margin5.2%
FCF margin7.7%
EBITDA margin18.5%
Returns
ROE12.1%
ROA4.9%
ROIC (approx.)10.9%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets56.4%
Debt / equity0.68x
Current ratio1.47x
Interest coverage6.66x
Cash quality & payout
Operating cash flow / net income2.62x
Accruals ratio-7.9%
Payout ratio51.1%
Capex / revenue5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.71B | $3.99B | $3.93B | $4.32B | $3.41B |
| Cost of revenue | $2.77B | $3.03B | $3.09B | $3.44B | $2.61B |
| Gross profit | $940.00M | $960.00M | $839.00M | $885.00M | $799.00M |
| R&D expense | $59.00M | $63.00M | $57.00M | $55.00M | $56.00M |
| SG&A expense | $260.00M | $283.00M | $253.00M | $258.00M | $289.00M |
| Operating income | $621.00M | $614.00M | $526.00M | $389.00M | $454.00M |
| Interest expense | $76.00M | $81.00M | $90.00M | $56.00M | $49.00M |
| Pretax income | $565.00M | $529.00M | $451.00M | $335.00M | $406.00M |
| Income tax | $196.00M | $111.00M | -$28.00M | $102.00M | $123.00M |
| Net income | $331.00M | $380.00M | $445.00M | $209.00M | $250.00M |
| EBITDA | $775.00M | $765.00M | $670.00M | $535.00M | $614.00M |
| EPS (basic) | 6.07 | 6.79 | 7.79 | 3.65 | 4.35 |
| EPS (diluted) | 6.02 | 6.72 | 7.73 | 3.62 | 4.34 |
| Dividends declared per share | 1.76 | 1.66 | 1.54 | 1.48 | 1.40 |
| Weighted avg. shares (diluted) | 54.20M | 55.70M | 56.50M | 56.90M | 56.80M |
| Balance sheet | |||||
| Cash & equivalents | $258.00M | $223.00M | $238.00M | $206.00M | $168.00M |
| Inventory | $504.00M | $552.00M | $585.00M | $664.00M | $523.00M |
| Current assets | $1.54B | $1.60B | $1.63B | $1.82B | $1.43B |
| PP&E, net | $1.71B | $1.53B | $1.41B | $1.27B | $1.38B |
| Goodwill | $134.00M | $133.00M | $134.00M | $129.00M | $140.00M |
| Intangibles | $55.00M | $53.00M | $60.00M | $63.00M | $100.00M |
| Total assets | $3.81B | $3.74B | $3.60B | $3.52B | $3.31B |
| Current liabilities | $957.00M | $772.00M | $822.00M | $1.10B | $1.15B |
| Short-term debt | $260.00M | $8.00M | $8.00M | $7.00M | $373.00M |
| Long-term debt | $856.00M | $1.09B | $1.09B | $1.09B | $717.00M |
| Total debt | $1.12B | $1.09B | $1.10B | $1.10B | $1.09B |
| Total liabilities | $2.11B | $2.15B | $2.20B | $2.49B | $2.22B |
| Shareholders' equity | $1.55B | $1.43B | $1.26B | $898.00M | $947.00M |
| Net debt | $858.00M | $872.00M | $864.00M | $890.00M | $922.00M |
| Shares outstanding | 52.84M | 54.30M | 55.24M | 56.25M | 56.73M |
| Cash flow statement | |||||
| Operating cash flow | $665.00M | $692.00M | $595.00M | $100.00M | $257.00M |
| Capital expenditure | $274.00M | $241.00M | $244.00M | $211.00M | $195.00M |
| Free cash flow | $391.00M | $451.00M | $351.00M | -$111.00M | $62.00M |
| Investing cash flow | -$298.00M | -$235.00M | -$214.00M | -$118.00M | -$186.00M |
| Financing cash flow | -$336.00M | -$415.00M | -$403.00M | $145.00M | -$60.00M |
| Depreciation & amortization | $154.00M | $151.00M | $144.00M | $146.00M | $160.00M |
| Stock-based compensation | $24.00M | $25.00M | $20.00M | $23.00M | $21.00M |
| Dividends paid | $96.00M | $93.00M | $88.00M | $84.00M | $80.00M |
| Share buybacks | $168.00M | $172.00M | $98.00M | $53.00M | $3.00M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.